Cure & Advancements/April 11, 2025/2 min read

First Human Trial Begins for ASITI-201, an Immunotherapy Designed to Protect Insulin-Producing Cells

Researchers at the University of Queensland have started a clinical trial of a new drug that aims to rebalance the immune system in people recently diagnosed with Type 1 diabetes. The approach, tested successfully in mice, combines a pancreatic protein with vitamin D to calm immune attacks on insulin-producing cells.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

ASITI-201 is a new immunotherapy drug designed to help the immune system stop attacking pancreatic cells in Type 1 diabetes
The trial is enrolling adults over 18 who were diagnosed with Type 1 diabetes within the last 5 years
The drug combines a pancreatic protein with vitamin D and has shown promise in mouse models of the disease
The goal is to preserve remaining pancreatic function so people may need less insulin over time
This is an early-stage trial; results will determine whether the drug works as intended in humans

A New Approach to Type 1 Diabetes

In Type 1 diabetes, the immune system mistakenly identifies insulin-producing cells in the pancreas as a threat and attacks them. Currently, the only available treatment is insulin replacement to manage blood sugar levels. Researchers at the University of Queensland's Frazer Institute have developed ASITI-201, an immunotherapy aimed at a different strategy: retraining the immune system to protect these cells instead of destroying them.

The drug combines a protein derived from the pancreas with vitamin D, which is thought to help calm the immune response. This approach has been successful in controlling the disease in laboratory mouse models, providing the foundation for testing in humans.

How the Trial Works

The clinical trial, led by Professor Ranjeny Thomas and Dr. Aakansha Zala, is enrolling adults over age 18 who have been diagnosed with Type 1 diabetes within the last five years. Participants will be seen at the Translational Research Institute's Clinical Research Facility at Princess Alexandra Hospital in Brisbane.

The primary goal is to observe whether ASITI-201 changes the immune system in the way researchers predict. If successful, the drug could help preserve remaining pancreatic function in people with newly diagnosed Type 1 diabetes, potentially reducing the amount of insulin they need to inject.

Why This Matters

Most current Type 1 diabetes treatments focus on managing blood sugar after the damage is done. ASITI-201 takes a fundamentally different approach by attempting to address the underlying immune malfunction. If the drug can slow or stop the destruction of pancreatic cells, it could meaningfully improve quality of life and reduce the burden of daily insulin management.

This is an early-stage trial, and while results from animal models are encouraging, it is too early to predict how well the drug will work in humans or whether it will be safe and effective for widespread use.

Evidence label

Origin: news.uq.edu.au (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.